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Abstract
Background: In the Chinese traditional medicine, plant of Agastache rugosa (Fisch. & C.A. Mey.) Kuntze (A. rugosa)
has been used to treat nausea, vomiting and dispel damp. However, currently, few reports about the chemical
constituents, especially the non-volatile components of A. rugosa are available.
Methods: Through separation with various column chromatographies to elucidate the chemical constituents of A.
rugosa, the biological activities of the major constituents were investigated. The extracts and main constituents of
A. rugosa were evaluated for their anticoagulant effects by assaying the activated partial thromboplastin time (APTT)
, prothrombin time (PT), thrombin time (TT) and fibrinogen (FIB) in vitro.
Results: Seven known compounds (namely compounds 1–7) were isolated from the aerial parts of A. rugosa. They
were identified as methyl hexadecanoate (1), β-sitosterol (2), acacetin (3), ursolic acid (4), apigenin (5), protocatechuic
acid (6) and tilianin (7), respectively. Compounds 1 and 6 were isolated from the genus Agastache for the first time,
and compound 4 was obtained from the plants for the first time. The results showed that the extract of A. rugosa
had a significant procoagulant activity by shortening the time of PT (P < 0.001) and increasing FIB content (P < 0.001),
as compared with Vitamin K1. While its major constituents acacetin and tilianin exhibited significant anticoagulant
activities by prolonging the times of PT, APTT, TT and reducing FIB content (P < 0.001), as compared with blank control
group.
Conclusions: The total extract of A. rugosa possessed significant procoagulant activity, while its main components,
acacetin and tilianin possessed significant anticoagulant activities. Further investigation should be pursued to find
out the bioactivity components responsible for the procoagulant action of the plant.
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Background
Agastache rugosa (A. rugosa), a medicinal plant belong-
ing to the family Lamiaceae, is native to Korea, Japan,
and China. A. rugosa shows the taste and thermal prop-
erties as pungent (acrid) is slightly warm and can the
channel affiliations to enter spleen, stomach and lung. A.
rugosa has been used in folk medicine to treat a variety
of diseases, including cholera, vomiting, miasma and
other intestinal disorders [1–4]. According to Trad-
itional Chinese Medicine theory, A. rugosa is classified
as an aromatic and damp dissolving herb. Thus it has
been widely used as an effective herbal drug to cure the
diseases of human pathogenic summer-heat and damp-
ness virulence in clinical in China.
According to the records, the use of A. rugosa as a
medicinal plant can be traced back to the Eastern Han
dynasty (25 AD - 220 AD) in China. Pharmacological in-
vestigation showed that A. rugosa possessed antibacterial
[5], anti-HIV integration activities [6], antioxidant [7],
cardiovascular [8, 9], cytoprotective activity and other
activities [10, 11]. Chemical studies showed that the
chemical compositions of A. rugosa mainly contained
essential oils, terpenoids, flavonoids and other constitu-
ents [11–13]. A. rugosa was collected in “Chinese
Pharmacopoeia” as one of genuine medicinal materials
before 1977, while “Chinese Pharmacopoeia” has only
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Because of this, A. rugosa was out of the scope of genu-
ine medicinal materials, and thus the research interest in
utilization of A. rugosa was reduced. Therefore, very few
the studies on its chemical constituents and bioactivities
have been available, in the recent years. In view of its
abundant wild resource and diverse biological activities,
it is necessary to study on its chemical constituents and
to elucidate its chemical constituents and biological
activities.
Thrombotic disease is a serious threat to human life
and health and its incidence is ranked the highest one
among various diseases. The incidence of thrombotic
has still been displaying an increasing tendency. In the
recent years, the studies on thrombotic disease are be-
coming one of the key points and hot spots in modern
medicine. Drug therapy has played an important role in
the prevention and treatment this disease. Currently, on
the medicinal market, there are only three main types of
anti-thrombotic drugs, including anticoagulant drugs,
anti-platelet drugs and thrombolytic drugs. However,
these drugs generally have greater adverse reactions and
their prices are quiet high. Therefore, developing a safe,
effective and low-cost anti thrombotic drug is an urgent
need for clinical drug therapy for this disease.
Thrombosis is the proximate cause of some vascular
disorders [14]. It has been shown that high-fat hyperlip-
idemia, obesity, hypertension, atherosclerosis, coronary
heart disease, myocardial infarction, cerebral thrombosis
and a series of cardiovascular and cerebrovascular dis-
eases are associated with abnormal lipid metabolism.
The main inducement include high levels of low-density
lipoprotein-cholesterol (LDL-C), low levels of high dens-
ity lipoprotein-cholesterol (HDL-C), the increase of free
radicals and lipid peroxidation [15]. Recently, there are
increasing interests in the biomedical field to isolate
thrombolytic agents and anti-thrombotic compounds
from food and natural sources, which are presumed to
be safer and more effective. Since A. rugosa exhibits a
cardiovascular protective effect, we hypothesized that A.
rugosa may have anti-coagulation effect. A literature sur-
vey implicated that there have been no reports on the
anti-coagulation activity of A. rugosa. Thus this study
aimed to investigate the chemical constituents and the
coagulation activity of A. rugosa.
Methods
Chemicals and material
1H NMR and 13C NMR spectra of chemical components
of A. rugosa were measured on a Bruker AscendTM 400
spectrometer (Bruker Corporation, Billerica, MA, USA).
Rotating evaporation instrument EYELA was purchased
from Tokyo Physical and Chemical Equipment Co., Ltd.
(Japan). A CXTH LC-3000 preparative HPLC system
was obtained from Beijing Chuangxintongheng Science
and Technology Co., Ltd. (China) and used for the high-
performance column chromatography (HPLC) and
equipped with binary pumps, an UV/VIS detector, and a
manual injection valve. Preparative medium pressure li-
quid chromatographic (MPLC) separation was per-
formed using a Sepacore glass column c-690 that was
filled with Silica gel (60 mesh, 500 g). Silica gel GF 254
Thin Layer Chromatography (TLC) and Silica gel (40–
80 mesh, 200–300 mesh) were purchased from Yantai
Huiyou Development co., Ltd (Shandong, China). Silica
gel H was made by Qingdao Haiyang Chemical Co., Ltd
(Shandong, China). Column chromatography was per-
formed over Sephadex LH-20 (Pharmacia Kalamazoo,
MI, USA). Centrifugation was performed on Shanghai
Anting TGL-16gr centrifugal.
Plant material
A. rugosa (Fisch. et Mey.) O. Ktze was originally col-
lected in October 2013 from the Suzhou region of
Jiangsu Province, China and identified by Professor
Changqin Li. A voucher specimen (201310231) was
deposited in the Institute of Traditional Chinese Medi-
cine, Henan University (Kaifeng, Henan, China).
Extraction and isolation
The air-dried aerial parts of A. rugosa (2.8 Kg) were ex-
tracted with 70% ethanol at 50 °C (3 × 15 L, 6 h) to yield
the crude extract (Ar.TE 178 g) after filtration and solv-
ent evaporation using a rotary evaporator. The extract
(178 g) was dissolved in H2O (500 mL), and extracted by
petroleum, ethyl acetate and n-butanol in turn, and the
recovered solvents were decompressed to obtain petrol-
eum ether site (Ar.Pe, 11.8 g), ethyl acetate part (Ar.Ea,
19 g) and n-Butanol site (Ar.Bu, 25.2 g), respectively.
Ar.Ea was separated by medium pressure liquid chro-
matography (MPLC) that was filled with silica gel H,
eluted with a stepwise-gradient, in sequence, of petrol-
eum ether-ethyl acetate (100:1–1:1, v/v), chloroform-
methanol (50:1–2:1, v/v) to afford 8 fractions (F1–F8)
based on TLC analyses. F2 (1.54 g) was subjected to
decompressed chromatographic column of silica gel H
with a gradient of petroleum ether-CHCl3 (1:0–0:1, v/v)
to afford 4 fractions (F2–1-F2–4). The separation of F2–4
using Sephadex LH-20 (petroleum ether/CHCl3/MeOH,
9:9:2, v/v/v) successively afforded compound 1 (25 mg)
and F2–4–1. F2–4–1 was firstly subjected to ordinary pres-
sure chromatographic columns of silica gel H with
petroleum ether-CHCl3 (1:10–0:1, v/v) and then through
re-crystal to obtain compound 2 (28.7 mg). F4 (1.72 g)
was subjected to decompressed chromatographic col-
umn of silica gel H with petroleum ether-ethyl acetate
(40:1–0:1, v/v) and then separated using Sephadex LH-
20 (CHCl3/MeOH, 1:1, v/v) to obtain compound 3
(15.8 mg). F5 was subjected to decompressed
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chromatographic column of silica gel H with petroleum
ether-ethyl acetate (10:1–0:1, v:v) to obtain Fa and Fb. Fb
was subjected to decompressed chromatographic col-
umn of silica gel H with CHCl3-acetone (1:0–1:1, v/v)
and Sephadex LH-20 (CHCl3/MeOH, 1:1, v/v) to obtain
compounds 3 (16.3 mg) and compounds 4 (33.4 mg).
Compounds 3 (63.8 mg) and 4 (145.7 mg) were enriched
in the same way from F6 and F7. F7 was subjected to de-
compressed chromatographic column of silica gel H
with CHCl3/acetone (50:1–0:1, v:v) to obtain F7–1 and
F7–2, and then F7–1 was separated using Sephadex LH-20
(CHCl3/MeOH, 1:1, v/v) to obtain compound 5 (3 mg).
F7–1 was subjected to decompressed chromatographic
column of silica gel H with CHCl3-MeOH (1:0–1:1, v/v)
and Sephadex LH-20 (CHCl3/MeOH, 1:1, v/v) to obtain
compound 6 (21.4 mg).
Ar.Bu was separated by MPLC that was filled with
silica gel H, eluted with CHCl2-MeOH (1:0–1:1, v/v) to
afford 7 parts (P1–P7) based on TLC analyses. P1 was
separated with Sephadex LH-20 (CHCl2/MeOH, 1:1, v/
v) to obtain compound 3 (35.8 mg). The solubility of P3
was not good. P3 was washed with petroleum ether,
CHCl2, ethyl acetate, acetone and methanol and mixed
solvent of various proportions, to afford un-dissolved
substance compound 7 (235.3 mg).
The Activated Partial thromboplastin time (APTT),
Prothrombin Time (PT), Thrombin Time (TT) and
Fibrinogen (FIB) Assays in Vitro
Blood samples were drawn from Rabbit’s Auricular Vein
(NO: 2015–035). Before collection, the sodium citrate
(38 mg/mL, 400 μL) was placed in a 4 mL centrifuge
tube to prevent blood clotting. Plasma was then sepa-
rated from the blood by centrifugation at 3000 rpm 5 °C
for 15 min. APTT and PT were determined according to
the method described previously [16]. In brief, plasma
(100 μL) was mixed with 20 μL of samples, APTT assay
reagent (100 μL) was added and incubated for 5 min at
37 °C, and then 25 mM CaCl2 (100 μL) was added.
Clotting times were recorded. For PT assays, plasma
(100 μL) was mixed with 20 μL of samples and incu-
bated at 37 °C for 3 min. PT assay reagent (200 μL),
which was hatched at 37 °C for 3 min, was then added
and clotting time was recorded. TT and FIB were deter-
mined according to the manufacturer’s recommenda-
tions (Shanghai Sun Biotech Co., Ltd, China).
For all the tests mentioned above, blank solvent
(dimethyl sulphoxide: Tween 80: normal saline = 2:1:17)
was used as negative control group, while the drugs of
breviscapine (13.3 mg/mL) and Vitamin K1 (5 mg/mL)
used in clinical were used as positive control groups. All
the samples were dissolved in blank solvent. The con-
centrations of compounds were 5 mg/mL and all the
extract samples were 15 mg/mL. PT, APTT, TT and FIB
tests were conducted by Semi-Automated Coagulation
Analyzer (CPC Diagnostics Pvt. Ltd, India).
Statistical analysis
The results were expressed as the arithmetic mean plus
or minus standard deviation. Numerical statistics were
performed using SPSS19.0 software with single factor
analysis of variance (ANOVA One-Way) to determine
the significant difference. The difference between groups
with P < 0.05 and P < 0.001 were regarded as significant
and highly significant, respectively. Results were shown
in Table 1.
Results
Chemical constituents in A. rugosa
Compound 1: was colorless oily liquid with melting
point (mp) at 28–30 °C. The molecular formula was
determined to be C17H34O2. EI-MS m/z: 270[M]
+. 1H-
NMR (CDCl3, 400 MHz) δ: 0.87 (3H, t, J = 8Hz, 4Hz, H-
16), 1.25 (24H, s, H-4–15), 1.61 (2H, m, H-3), 2.29 (2H,
t, J = 8 Hz, 8Hz, H-2), 3.66 (2H, s, H-1′). 13C-NMR
(CDCl3, 100 MHz) δ: 174.2 (C-1), 51.35 (C-1′), 34.11
(C-2′), 24.96 (C-3), 29.15 (C-4), 29.24 (C-5), 29.34 (C-6),
29.67 (C-7, C-11), 29.58 (C-12), 29.44 (C-13), 31.91 (C-
Table 1 The effects of A. rugosa extracts, acacetin and tilianin on APTT, PT, TT, and FIB in vitro ( x ± s)
Groups APTT (S) PT (S) TT (S) FIB (g/L)
Blank 19.5000 ± 0.216 11.5750 ± 0.275 14.2750 ± 0.13 3.7250 ± 0.132
Breviscapine 22.5000 ± 0.216*** 14.0000 ± 0.163*** 20.7750 ± 0.15*** 6.1633 ± 0.035***
Vitamin K1 16.5500 ± 0.129
***### 10.9333 ± 0.115***### 13.5000 ± 0.26***### 4.6000 ± 0.145***###
Ar.TE 19.3750 ± 0.320###&&& 10.5000 ± 0.258***###& 14.5250 ± 0.19##&&& 6.7150 ± 0.153***###&&&
Ar.Pe 16.0500 ± 0.238***###&& 10.2500 ± 0.191***###&&& 18.6475 ± 0.20***###&&& 3.8350 ± 0.066###&&&
Ar.Ea 16.625 ± 0.222***### 11.0500 ± 0.238**### 17.2450 ± 0.19***###&&& 3.7175 ± 0.111###&&&
Ar.Bu 16.0967 ± 0.295***###& 10.8750 ± 0.275***### 15.2750 ± 0.25***&&& 3.9100 ± 0.071**###&&&
Acacetin 20.7225 ± 0.121***###&&& 12.5500 ± 0.311***###&&& 20.2750 ± 0.26***##&&& 2.8125 ± 0.142***###&&&
Tilianin 20.7500 ± 0.191***###&&& 12.2000 ± 0.082***###&&& 16.7475 ± 0.19***###&&& 3.1425 ± 0.111***###&&&
Note: results were expressed as mean ± SD, n = 4. Compared with blank: ***P < 0.001; 0.001 < **P < 0.01; Compared with breviscapine: ###P < 0.001; 0.001 < ##P < 0.01.
Compared with Vitamin K1: &&&P < 0.001, 0.001 < &&P < 0.01, &P < 0.05
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14), 22.67 (C-15), 14.06 (C-16). The above spectral data
were basically consistent with those reported previously
[17] and thus, compound 1 was identified as methyl
hexadecanoate.
Compound 2: this compound was a white powder with
mp at 136–137 °C. The molecular formula was deter-
mined to be C29H50O. EI-MS m/z: 414[M]
+. When com-
pound 2 was compared with reference substance of β-
sitosterol, no difference was seen between them in term
of the TLC detection. Its Rf values were the same in
three different developing agents, and the coloration
were the same. The samples were mixed with reference
substance of β-sitosterol, and the melting point of the
mixture was not decreased. Thus compound 2 was iden-
tified as β-sitosterol.
Compound 3: this compound is a yellow, needle-shaped
crystal with mp at 261–262 °C. The molecular formula
was determined to be C16H12O5. EI-MS m/z: 283 [M-H]
−.
1H-NMR (DMSO-d6, 400 MHz) δ: 12.88 (1H, s, 5-OH),
8.01 (2H, d, J = 8.0 Hz, H-2′, 6′), 7.11 (2H, d, J = 8.0Hz, H-
3′, 5′), 6.82 (1H, s, H-3), 6.50 (1H, s, H-8), 6.20 (1H, s, H-
6), 3.84 (3H, s, −OCH3).
13C-NMR (DMSO-d6, 100 MHz)
δ: 122.98 (C-1), 163.61 (C-2), 103.67 (C-3), 181.97 (C-4),
157.57 (C-5), 94.29 (C-6), 164.45 (C-7), 99.14 (C-8),
162.54 (C-9), 103.94 (C-10), 161.61 (C-4′), 128.52 (C-
2′, 6′), 114.82 (C-3′, 5′), 55.75 (4′-OCH3). The above
data were basically consistent with those reported in
the reference [18]. Thus, compound 3 was identified
as acacetin.
Compound 4: this compound was a white crystalline
with mp at 240–245 °C. The molecular formula was de-
termined to be C30H48O3. EI-MS m/z: 456[M]
+. 1H-
NMR (C5D5N, 400 MHz) δ: 5.50 (1H, s, H-12), 3.46 (1H,
dd, J = 4.0, 8.0Hz, H-3), 2.33 (1H, q, H-18), 1.25 (3H, s,
H-27), 1.24 (3H, s, H-26), 1.06 (3H, s, H-23), 0.95
(3H, d, J = 8.0Hz, H-29), 0.90 (3H, s, H-24), 1.02 (3H,
d, J = 8.0Hz, H-30), 1.03 (3H, s, H-25). 13C-NMR
(C5D5N, 100 MHz) δ: 37.17 (C-1), 27.85 (C-2), 77.88
(C-3), 38.84 (C-4), 55.57 (C-5), 18.52 (C-6), 33.32 (C-
7), 39.73 (C-8), 47.78 (C-9), 39.23 (C-10), 23.64 (C-
11), 125.38 (C-12), 138.99 (C-13), 42.25 (C-14), 28.53
(C-15), 24.65 (C-16), 47.78 (C-17), 53.30 (C-18), 39.14
(C-19), 39.09 (C-20), 30.81 (C-21), 37.03 (C-22), 28.43
(C-23), 15.40 (C-24), 16.27 (C-25), 17.23(C-26), 23.36
(C-27), 179.55 (C-28), 17.18 (C-29), 21.11 (C-30). The
above data were basically consistent with those re-
ported in the reference [19]. Thus, compound 4 was
identified as ursolic acid.
Compound 5: this compound was a yellow, needle-
shaped crystal with mp at 275–276 °C. The molecu-
lar formula was determined as C15H10O5. EI-MS m/
z: 270 [M]−。1H-NMR (DMSO-d6, 400 MHz) δ:
12.95 (1H, s, 5-OH), 10.81 (1H, s, 7-OH), 10.33 (1H,
s, 4′-OH), 7.91 (2H, d, J = 8.0 Hz, H-2′, 6′), 6.92
(2H, d, J = 4.0 Hz, H-3′, 5′), 6.77 (1H, s, H-3), 6.48
(1H, s, H-8), 6.19 (1H, s, H-6). 13C-NMR (DMSO-d6,
100 MHz) δ: 164.10 (C-2), 102.83(C-3), 181.72 (C-4),
161.43 (C-5), 98.82 (C-6), 163.74 (C-7), 93.94 (C-8),
157.29 (C-9), 103.68 (C-10), 121.17 (C-1′), 128.44
(C-2′, 6′), 115.94 (C-3′, 5′), 161.14 (C-4′). The
above data were basically consistent with those
reported in reference [18]. Thus the compound 5
was identified as apigenin.
Compound 6: this compound was a yellow-brown,
needle-shaped crystal with mp at 199–200 °C. The mo-
lecular formula was determined as (HO)2C6H3COOH.
EI-MS m/z: 153[M]−. 1H-NMR (DMSO-d6, 400 MHz) δ:
7.33 (1H, s, H-2), 7.29 (1H, d, J = 8.0 Hz, 6-H), 6.79 (1H,
d, J = 8.0Hz, 5-H). 13C-NMR (DMSO-d6, 100 MHz) δ:
121.87 (C-1), 116.74 (C-2), 145.03 (C-3), 150.15 (C-4),
115.31 (C-5), 122.03 (C-6), 167.43 (C-7). The above data
were basically consistent with those reported in the
reference [20]. Thus, the compound 6 was identified as
protocatechuic acid.
Compound 7: this compound was a light yellow
powder with mp at 256–257 °C. The molecular for-
mula was determined to be C22H22O10. EI-MS m/z:
446[M]+. 1H-NMR (DMSO-d6, 400 MHz) δ: 12.91
(1H, s, 5-OH), 8.07 (2H, d, J = 8.0 Hz, H-2′, 6′), 7.14
(2H, d, J = 8.0 Hz, H-3′, 5′), 6.95 (1H, s, H-3), 6.86
(1H, s, H-8), 6.46 (1H, s, H-6), 5.06 (1H, d, J = 8.0Hz,
Glc-H-1′′), 3.71 (1H, m, Glc-H-2′′), 3.18 (1H, m,
Glc-H-3′′), 3.45 (1H, m, Glc-H-4′′), 3.47 (1H, m,
Glc-H-6′′b). 13C-NMR (DMSO-d6, 100 MHz) δ:
163.00 (C-2), 103.78 (C-3), 181.98 (C-4), 156.93 (C-5),
99.56 (C-6), 163.80 (C-7), 94.90 (C-8), 162.44 (C-9),
105.36 (C-10), 122.66 (C-1′), 128.39 (C-2′, 6′), 161.07
(C-4′), 114.59 (C-3′, 5′), 55.54 (4′-OCH3), 99.94 (C-2′
′), 73.08 (C-2′′), 77.15 (C-3′′), 69.57 (C-4′′), 76.41 (C-5′
′), 60.60 (C-6′′). The above data were basically consist-
ent with those reported in the reference [21]. Thus,
compound 7 was identified as tilianin. All the sruc-
tures of compound 1 ~ 7 were shown in Fig. 1.
Coagulation time test in vitro
In Fig. 2, compared with the blank group, both acacetin
and tilianin could significantly prolong APTT (P < 0.001)
while Ar.Pe, Ar.Ea, and Ar.Bu had highly significant
effects on promoting blood coagulation (P < 0.001).
Compared with the breviscapine, the effects of acacetin
and tilianin were not better than that of the positive
control (P < 0.001). Compared with the Vitamin K1,
Ar.Pe and Ar.Bu had significant effects on promoting
coagulation (0.01 < P < 0.001 and P < 0.05, respectively).
Results shown in the Fig. 3 indicated that compared
with the blank group, acacetin and tilianin could signifi-
cantly prolong PT (P < 0.001) while Ar.TE, Ar.Pe, Ar.Ea,
Ar.Bu had highly significant effects on promoting blood
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coagulation (P < 0.001 and 0.001 < P < 0.01, respectively).
Compared with the breviscapine, the effects of acace-
tin and tilianin were not better than the positive
control (P < 0.001). Compared with the Vitamin K1,
Ar.TE and Ar.Pe had significant effects on promoting
coagulation (P < 0.05 and P < 0.001, respectively).
As shown in Fig. 4, compared with the blank group,
Ar.Pe, Ar.Ea, Ar.Bu, acacetin and tilianin could signifi-
cantly prolong TT (P < 0.001). Compared with the bre-
viscapine, the anticoagulant activity of the positive
control was the best one (P < 0.001).
Results shown in the Fig. 5 indicated that compared
with the blank group, acacetin and tilianin could signifi-
cantly decrease the FIB content (P < 0.001). Compared
with the Vitamin K1, Ar.TE could significantly increase
FIB content (P < 0.001).
Discussion
Through the chemical analysis, we found that ursolic
acid, acacetin and tilianin were the main chemical com-
ponents in A. rugosa. These compounds have been
known to have a wide range of biological activities and
play a role in triggering cardiovascular activities. For
instance, Li et al. [22] reported that ursolic acid could
promote the neuroprotection by activating nuclear
factor-erythroid 2-related factor-2 pathway after cerebral
ischemia in mice. Yang et al. [23] reported that ursolic
acid could reestablish the intracellular redox state. Li et
al. [24] demonstrated that the natural compound acace-
tin was an atrium-selective agent that prolonged the
atrial effective refractory period without prolonging the
corrected Q wave - T wave (QT) interval and effectively
prevented atrial fibrillation (AF) in anesthetized dogs
after intraduodenal administration. Tilianin mediated
relaxation mainly by an endothelium-dependent manner,
probably due to NO release, and also through an
endothelium-independent pathway by opening K+ chan-
nels, both could cause the antihypertensive effect [25].
Fig. 1 Structures of compound 1 ~ 7
Fig. 2 The effects of A. rugosa extract, acacetin and tilianin on APTT
in vitro
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There have been no reports in the literature about the
anticoagulant activity of A. rugosa. In this study, we
found that the main chemical components, including
ursolic acid, acacetin and tilianin of A. rugosa had
anticoagulant-related activity. Anticoagulant activities of
Ar.TE, Ar.Pe, Ar.Ea, Ar.Bu, acacetin and tilianin were
investigated in the experiment in vitro.
The results obtained in this study are quite interest-
ing. Firstly, Ar.TE had an activity of promoting co-
agulation as shown by PT and FIB while Ar.Pe, Ar.Ea
and Ar.Bu had procoagulant activities as shown by
APTT and PT. Acacetin, ursolic acid and tilianin all
displayed significant anticoagulant activities as shown
by PT, APTT, TT and FIB. The activities of Ar.Pe,
Ar.Ea and Ar.Bu were different because their main
components were different. For instance, acacetin and
ursolic acid were the main components in the Ar.Ea
while tilianin was one of the main components in the
Ar.Bu. The difference in main components might be
due to following reasons: the compounds having a
great effect might not be isolated or the remaining
compounds could have a great effect on promoting
coagulant, though their contents might be very low.
The chemical components of plant medicines are
complex, and the pharmacological effects can be the
interactions of multi-components, multi targets to-
gether, either synergistically or antagonistically. There
might be no any compounds having great effects on
promoting coagulation. This is the common function
of several components.
As compared with the blank group, both acacetin
and tilianin exhibited significant anticoagulant activ-
ities as demonstrated by PT, APTT, TT and FIB as-
says. Acacetin and tilianin are natural flavonoid
compounds with abundant sources from plant origin.
The techniques for isolation and separation of both
compounds are simple and easy to operate. The acute
toxicity experiment of acacetin showed that it was a
safe clinical medication (LD50 = 933 mg/kg) [26]. The
acute toxicity test of tilianin had not been done yet
and there was no report about its toxicity. Therefore,
both acacetin and tilianin may have a good pharma-
ceutical prospect. Being cheap, safe and effective, they
are in line with the requirements of today’s market
fort anti-thrombotic drugs. Of course, the mechanism
underlying their anti-coagulation activity need to be
further investigated.
A. rugosa has been commonly used to treat summer
heat-dampness and stomach flu etc. Because A. rugosa is
also an aromatic plant, the studies on A. rugosa have
been mostly focused on the volatile components. The re-
search on non volatile component of A. rugosa was
mainly initiated in the 1990s [27–30], and until recently,
there were have been few studies on the chemical com-
position and biological activity of A. rugosa. Thus, we in-
vestigated the chemical composition and coagulation
activity of A. rugosa and found that Ar.TE had a signifi-
cant procoagulant activity, compared with Vitamin K1.
Acacetin and tilianin had significant anticoagulant activ-
ity, as compared with the blank group. Further investiga-
tion should be pursued to find the effect of A. rugosa,
acacetin and tilianin in vivo. Since the effects of acacetin
and tilianin are different from those of A. rugosa, it
Fig. 4 The effects of A. rugosa extract, acacetin and tilianin on TT
in vitro
Fig. 3 The effects of A. rugosa extract, acacetin and tilianin on PT
in vitro
Fig. 5 The effects of A. rugosa extract, acacetin and tilianin on FIB
in vitro
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should be noted that other active components in the ex-
tract remained to be further identified and characterized.
Conclusions
A. rugosa has been a traditional Chinese medicinal plant.
The previous studies on A. rugosa were mainly focused
on the volatile components and its traditional pharma-
cological activity. In the present study, we found for the
first time that the A. rugosa had a significant coagulant
activity. The total extract of A. rugosa possessed signifi-
cant procoagulant activity while acacetin and tilianin
identified as the main components of A. rugosa had a
significant anticoagulant activity in vitro. As a novel,
effective and promising drug for the treatment of various
coagulation disorders, A. rugosa may be beneficial for
the individual with high risks of with hemophilia and
other bleeding disorders. Acacetin and tilianin were
natural flavonoid compounds, whose plant origin was
abundant and isolation and separation technique were
simple and easy to operate. They might have a good
pharmaceutical prospect. Being cheap, safe and effective,
they can meet requirements of today’s market about
antithrombotic drugs.
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